Caitlyn
(Amrubicin)Phase 3Small molecule
Bristol-Myers SquibbAmrubicin is a chemotherapy drug used to treat certain types of lung cancer, particularly small cell lung cancer. It works by damaging cancer cell DNA to stop the cancer cells from growing and dividing.[1] Caitlyn is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Caitlyn is one of 222 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
8
Indications
19
Total Trials
4
Active Trials
221
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Caitlyn
Bristol-Myers SquibbPhase 3
Trodelvy
GileadPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Ibrance
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer9 trials
Show 6 more trials
Breast Cancer2 trials
Lung Cancer1 trial
5 more indications
Relapsed or Refractory1 trial
Urothelial Carcinoma1 trial
Soft Tissue Sarcoma1 trial
Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amrubicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- DNA Topoisomerase II Alpha Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company